Celcuity Inc
Headquarters country
United States
Registry sponsor category
Industry
- Company name
- Celcuity Inc
- Organisation type
- Industry
- Registered legal name
- CELCUITY INC.
- US industry code (SIC)
- Services-medical laboratories
- Registry sponsor category
- Industry
- Celcuity, LLC
- Celcuity Inc
- SEC filer number (CIK)
- 0001603454
- Legal Entity Identifier (LEI)
- 25490070W7UU7W2SEY87
Related records
Trials (11)
- A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
- Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
- Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
- Fulvestrant + Neratinib In Breast Cancer
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
- Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
- Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
- Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling